Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CV Therapeutics Seeks Ranexa Labeling Changes Based on MERLIN Study

This article was originally published in The Pink Sheet Daily

Executive Summary

sNDA includes new analysis of MERLIN-TIMI 36 data, which should eliminate safety concerns around QTc prolongation, clinical researchers report at the European Society of Cardiology.

You may also be interested in...



Sales Reps Will Make Case For Ranexa In First-Line Angina

New label, which exceeded CV Therapeutics’ expectations, highlights reduction of hemoglobin A1c levels and arrhythmias.

Sales Reps Will Make Case For Ranexa In First-Line Angina

New label, which exceeded CV Therapeutics’ expectations, highlights reduction of hemoglobin A1c levels and arrhythmias.

CV Therapeutics Inks Ex-U.S. Ranexa Deal

With Menarini, angina drug will launch in the U.K. and Germany early next year.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel